COMIRNATY

Approval Id: e5fd4b8efc4ae90d
Drug Approval Canada Name: COMIRNATY
Product Name: COMIRNATY
Status: Marketed
Status Date: 2024-09-24
Original Market Date: 2023-10-23
Din: 02541858
Drug Class: Human
Dosage Form: Suspension
Route Of Administration: Intramuscular
Schedule: Schedule D
Ahfs: 80:12.00
Atc Original: J07BN01 COVID-19, RNA-BASED VACCINE
Atc Name: j 07 bn 01
Aig Number: 0166244003
Company Name: BioNTech Manufacturing GmbH
Company Address: An Der Goldgrube 12, Mainz, Rheinland-Pfalz, Germany, 55131
Company Detail Path: /organization/biontech-manufacturing-gmbh

*SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER

10 MCG / 0.3 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

e5fd4b8efc4ae90d

Type

Standard